Intelligent life sciences: How the AI transformation succeeds

Artificial intelligence (AI) has established itself as a driving force in the life sciences industry. From drug development and clinical trials to logistics, authorisation and patient interaction: AI accelerates processes, enables new business models and increases operational efficiency. Today, the question is no longer whether AI delivers added value, but how companies can realign their structures and processes to realise the full potential of this technology.

The report "Intelligent life sciences" sheds light on how leading companies in the industry are driving change - by adapting their operating models, breaking down silos and promoting AI-driven agility. The report also provides practical recommendations on how companies can develop a value-driven approach to the use of AI to accelerate innovation, unlock new growth opportunities and maximise the return on their AI investments.

To shed light on the current state of AI integration and technology-related issues, KPMG International conducted a quantitative survey of 1,390 decision-makers from eight industries (banking, retail, energy, healthcare, industrial manufacturing, life sciences, technology and insurance) in eight countries (Australia, Canada, China, France, Germany, Japan, the United Kingdom and the United States). This cross-industry study involved 183 life sciences executives, 51 per cent of whom were at C-suite level. They represent leading diagnostics companies as well as medium-sized pharmaceutical, biotech, medical technology and service companies in the pharmaceutical industry.